<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01568736</url>
  </required_header>
  <id_info>
    <org_study_id>STAIR 7003</org_study_id>
    <nct_id>NCT01568736</nct_id>
  </id_info>
  <brief_title>B7 Coreceptor Molecules in Hyper IgD Syndrome Form of Mevalonate Kinase Deficiency</brief_title>
  <acronym>HIDS-MKD</acronym>
  <official_title>B7 Coreceptor Molecules as Clinically-Relevant Surrogate Biomarkers in the Hyper IgD Syndrome (HIDS) Form of Mevalonate Kinase Deficiency (MKD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michigan Technological University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Michigan Technological University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hyper IgD syndrome (HIDS) is an inflammatory disease caused by mevalonate kinase
      deficiency. There is no cure, and available treatments of HIDS febrile episodes have shown
      limited clinical efficacy. The development of effective interventions for HIDS is limited by
      our poor understanding of the disease. The goal of the study is to better characterize the
      inflammatory response during HIDS episodes and to determine the relationship between this
      response and blood and urine markers of mevalonate kinase deficiency. This knowledge will
      help us learn more about the cause of the disease and should lead to the identification of
      new disease biomarkers that can be used to evaluate clinical efficacy in future therapeutic
      trials.

      The primary hypothesis is that the costimulatory B7 glycoprotein abnormalities identified in
      the murine MKD model will be recapitulated in sera obtained from human HIDS patients, either
      before, during or after febrile episodes. The secondary hypothesis is that B7 glycoprotein
      molecule levels will correlate with clinical symptomatic severity score, other known
      biomarkers of HIDS, markers of inflammation and or markers of isoprenoid metabolism.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Hyper IgD Syndrome</condition>
  <condition>Mevalonate Kinase Deficiency</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood Urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with Hyper IgD Syndrome (HIDS)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  any race or ethnicity

          -  diagnosed with HIDS

        Exclusion Criteria:

          -  parents' inability to donate blood

          -  currently having cancer, renal failure, diabetes, liver disease, thyroid diseases,
             major infectious diseases or immunodeficiency

          -  pregnancy

          -  inability to provide consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anna Simon, MD, PhD</last_name>
    <phone>+31 24 3618819</phone>
    <email>A.Simon@aig.umcn.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Michigan Techinical University</name>
      <address>
        <city>Houghton</city>
        <state>Michigan</state>
        <zip>49931</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>K. Michael Gibson, PhD, FACMG</last_name>
      <phone>906-487-2738</phone>
      <email>kmgibson@mtu.edu</email>
    </contact>
    <investigator>
      <last_name>K. Michael Gibson, PhD, FACMG</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William B Rizzo, MD</last_name>
      <phone>402-559-2560</phone>
      <email>wrizzo@unmc.edu</email>
    </contact>
    <investigator>
      <last_name>William B Rizzo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Steiner, MD</last_name>
      <phone>503-494-2783</phone>
      <email>steinerr@ohsu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jill Christie, MPAS, PA-C</last_name>
      <phone>503-494-4979</phone>
      <email>chrisjil@ohsu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Robert Steiner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radbound University of Nijmegen Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Simon, MD, PhD</last_name>
      <phone>+31 24 3618819</phone>
      <email>A.Simon@aig.umcn.nl</email>
    </contact>
    <investigator>
      <last_name>Anna Simon, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2012</study_first_submitted>
  <study_first_submitted_qc>March 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2012</study_first_posted>
  <last_update_submitted>March 30, 2012</last_update_submitted>
  <last_update_submitted_qc>March 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Michigan Technological University</investigator_affiliation>
    <investigator_full_name>Kenneth Michael Gibson</investigator_full_name>
    <investigator_title>Professor and Chair</investigator_title>
  </responsible_party>
  <keyword>Hyper IgD Syndrome (HIDS)</keyword>
  <keyword>Mevalonate Kinase Deficiency (MKD)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Mevalonate Kinase Deficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

